Drug Trial Radar · NCT06892522
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
602
Planned (sponsor's estimate)
Start
Jun 30, 2025
Primary completion
Dec 2035
Study completion Mar 2036
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety, efficacy, and pharmacokinetics of Etentamig and ABBV-2001 in adult participants with MM. Etentamig and ABBV-2001 are investigational drugs being developed for the treatment of MM. This study is broken into 8 substudies and each substudy consists of a dose escalation phase and dose expansion phase. Participants in substudies 1-4 will receive escalating doses of etentamig alone or with daratumumab and lenalidomide (DR), carfilzomib and dexamethasone (Kd) or lenalidomide (R), followed by etentamig at the dose levels established during the escalation phases alone or with DR, Kd and R. Participants in substudies 5-8 will receive up to two doses of ABBV-2001 or at the dose level(s) established during the escalation phases of ABBV-2001 with iberdomide, mezigdomide, pomalidomide or lenalidomide. Around 602 adult participants with MM will be enrolled at approximately 55 sites worldwide In substudies 1-3, participants will receive escalating doses of etentamig as Intravenous (IV) infusions, alone or with DR, R or Kd, followed by SC injections of etentamig at the dose levels established during the escalation phases alone or with DR or K. In substudy 4, participants will receive escalating doses of etentamig as Intravenous (IV) infusions followed by SC injections of etentamig at the dose levels established during the escalation phase with Lenalidomide. In substudies 5-8, participants will receive up to two doses of ABBV-2001 as subcutaneous (SC) injections, with oral iberdomide, mezigdomide, pomalidomide or lenalidomide followed by SC injections of ABBV-2001 at the dose level(s) established during the escalation phases with oral iberdomide, mezigdomide, pomalidomide or lenalidomide. The study duration is approximately 130 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.
Conditions
- Multiple Myeloma
Interventions
EtentamigDrug
Intravenous (IV) Infusion
LenalidomideDrug
Oral
DexamethasoneDrug
IV Injection
DaratumumabDrug
Subcutaneous (SC) Injection
DexamethasoneDrug
Oral
CarfilzomibDrug
Intravenous (IV) Infusion
MezigdomideDrug
Oral
IberdomideDrug
Oral
ABBV-2001Drug
Subcutaneous (SC) Injection
EtentamigDrug
Subcutaneous (SC) Injection
PomalidomideDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AE)sTime frame: Up to Approximately 130 Months
- Substudy 1: Dose-Limiting Toxicity (DLT) of Etentamig + Daratumumab and Lenalidomide (DR) in Participants with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM)Time frame: Up to Approximately 8 weeks
- Substudy 2: DLT of Etentamig Monotherapy as Maintenance in Participants with Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM)Time frame: Up to Approximately 8 Weeks
- Substudy 3: DLT of Etentamig +Carfilzomib and Dexamethasone (Kd) Combination in Participants with Relapsed or Refractory Multiple Myeloma (RR MM)Time frame: Up to Approximately 8 Weeks
- Substudy 4: DLT of Etentamig plus Lenalidomide when Given as Maintenance in Participants with TE NDMMTime frame: Up to Approximately 8 Weeks
- Substudy 5: DLT of ABBV-2001 in Combination with Iberdomide in Participants with RR MMTime frame: Up to Approximately 8 Weeks
- Substudy 6: DLT of ABBV-2001 in Combination with Mezigdomide in Participants with RR MMTime frame: Up to Approximately 8 Weeks
- Substudy 7: DLT of ABBV-2001 in Combination with Pomalidomide in Participants with RR MMTime frame: Up to Approximately 8 Weeks
- Substudy 8: DLT of ABBV-2001 in Combination with Lenalidomide in Participants with RR MMTime frame: Up to Approximately 8 Weeks
Locations
36 sites in 6 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center /ID# 273132
Duarte, California · Recruiting
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277911
Irvine, California · Recruiting
University Of California, San Francisco /ID# 271662
San Francisco, California · Recruiting
Colorado Blood Cancer Institute /ID# 273129
Denver, Colorado · Recruiting
Moffitt Cancer Center /ID# 272628
Tampa, Florida · Recruiting
Winship Cancer Institute of Emory University /ID# 274830
Atlanta, Georgia · Recruiting
Mount Sinai - The Tisch Cancer Institute /ID# 272470
New York, New York · Recruiting
Weill Cornell Medical College /ID# 272517
New York, New York · Recruiting
University of North Carolina at Chapel Hill /ID# 274667
Chapel Hill, North Carolina · Recruiting
Atrium Health Levine Cancer Institute /ID# 276193
Charlotte, North Carolina · Recruiting
Atrium Health Wake Forest Baptist Medical Center /ID# 274847
Winston-Salem, North Carolina · Recruiting
Oncology Hematology Care - Blue Ash /ID# 272918
Cincinnati, Ohio · Recruiting
The Ohio State University /ID# 271336
Columbus, Ohio · Recruiting
University of Texas - Southwestern Medical Center /ID# 274360
Dallas, Texas · Recruiting
Huntsman Cancer Institute /ID# 272575
Salt Lake City, Utah · Recruiting
Coffs Harbour Health Campus /ID# 272010
Coffs Harbour, New South Wales, Australia · Recruiting
Port Macquarie Base Hospital /ID# 275925
Port Macquarie, New South Wales, Australia · Recruiting
Westmead Hospital /ID# 271880
Westmead, New South Wales, Australia · Recruiting
Icon Cancer Care - South Brisbane /ID# 271836
South Brisbane, Queensland, Australia · Recruiting
Royal Adelaide Hospital /ID# 272629
Adelaide, South Australia, Australia · Recruiting
St Vincent's Hospital - Melbourne /ID# 276451
Fitzroy, Victoria, Australia · Recruiting
Peter MacCallum Cancer Centre. /ID# 272024
Melbourne, Victoria, Australia · Recruiting
The Perth Blood Institute - West Perth /ID# 272469
West Perth, Western Australia, Australia · Recruiting
Rambam Health Care Campus- Haifa /ID# 271364
Haifa, Israel · Recruiting
Hadassah Medical Center-Hebrew University /ID# 271362
Jerusalem, Israel · Recruiting
Rabin Medical Center. /ID# 271365
Petah Tikva, Central District, Israel · Recruiting
Soroka Medical Center /ID# 271367
Beersheba, Southern District, Israel · Recruiting
The Chaim Sheba Medical Center /ID# 271366
Ramat Gan, Tel Aviv, Israel · Recruiting
Nagoya City University Hospital /ID# 273529
Nagoya, Aichi-ken, Japan · Recruiting
University Hospital Kyoto Prefectural University of Medicine /ID# 275713
Kyoto, Kyoto, Japan · Recruiting
The University of Osaka Hospital /ID# 275791
Suita-shi, Osaka, Japan · Recruiting
Japanese Red Cross Medical Center /ID# 273530
Shibuya-ku, Tokyo, Japan · Recruiting
Oslo Universitetssykehus Ulleval /ID# 277915
Oslo, Norway · Recruiting
University Hospitals Birmingham NHS Foundation Trust /ID# 274620
Birmingham, United Kingdom · Recruiting
University Hospital of Wales /ID# 273446
Cardiff, United Kingdom · Recruiting
Hammersmith Hospital /ID# 274615
London, England, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.